News | June 23, 2025
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Subscribe To Our Newsletter & Stay Updated
